Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.24.1.u1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:    
Research and development $ 5,761,494 $ 13,388,343
General and administrative 3,861,251 3,908,682
Total operating expenses 9,622,745 17,297,025
Operating loss (9,622,745) (17,297,025)
Other income (expense), net:    
Other income (expense), net 2,909,097 229,507
Interest expense, net (177,015) (678,022)
Change in fair value of derivative liability 28,568 0
Foreign currency exchange gain (loss), net (36,676) 728
Other income (expense), net 2,723,974 (447,787)
Net loss $ (6,898,771) $ (17,744,812)
Earnings Per Share, Basic $ (0.83) $ (4.24)
Earnings Per Share, Diluted $ (0.83) $ (4.24)
Weighted Average Number of Shares Outstanding, Basic 8,310,508 4,181,556
Weighted Average Number of Shares Outstanding, Diluted 8,310,508 4,181,556
Comprehensive loss:    
Net Income (Loss) $ (6,898,771) $ (17,744,812)
Other comprehensive (loss) income :    
Change in unrealized (loss) gain on marketable debt securities (326,949) 57,623
Total other comprehensive (loss) income (326,949) 57,623
Total comprehensive loss $ (7,225,720) $ (17,687,189)